Mesoblast Stock News

Mesoblast Limited (NASDAQ: MESO ) presented new results from the landmark Phase 3 study of rexlemestrocel-L in 565 patients with chronic heart failure (CHF) with reduced ejection fraction (HFrEF). Data were shared at the American Heart Association annual Scientific Sessions. A single dose of rexlemestrocel-L on top of standard of care reduced the incidence of heart attacks or strokes by 65% Full story available on Benzinga.com

The S&P/ASX 200 Index firmed 0.4 per cent on Monday as Mesoblast shares rallied 11.8 per cent on positive results for a key therapy treating heart failure.

Drug developer Mesoblast (ASX:MSB) has spiked on the ASX today after announcing findings from a third-phase trial for its rexlemestrocel-L product in chronic heart failure.

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index Read More The post ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure appeared first on Stockhead .

Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Greatest Effect Seen in Setting of Inflammation NEW YORK, Nov. 14, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with reduced ejection fraction (HFrEF) were presented as a late breaking presentation at the American Heart Association (AHA) annual Scientific Sessions during a featured program titled Building on the Foundations of Treatment: Advances in Heart Failure Therapy''. The trial''s co-principal investigator Dr. Emerson Perin, Medical Director of Texas Heart Institute, and Clinical Professor, Baylor College of Medicine, presented new results from the landmark study showing a significant relationship between presence of systemic inflammation as quantified by high-sensitivity C-reactive protein (hs-CRP) and treatment benefit with rexlemestrocel-L on risk of cardiovascular mortality, heart attacks or strokes.

It''s been a very good day for Mesoblast shares The post Mesoblast (ASX:MSB) share price surges 9% higher on trial update appeared first on The Motley Fool Australia .

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the ra

Mesoblast Limited (NASDAQ: MESO) shares dived on Tuesday as the FDA raised more questions around its flagship drug candidate, and its annual loss widened.  What Happened: In the June quarter, Mes

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights an

Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2021 Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2021

Mesoblast Limited (NASDAQ: MESO) has announced the presentation of 90-day survival outcomes from the remestemcel-L trial in ventilator-dependent COVID-19 patients with moderate/severe acute respira

NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from

NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from t

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights an